Evidence map›Paper›PMID 41737598›Full record

ArticleCell biomaterials2025

Comparative analyses for plant virus-based cancer immunotherapy drug development.

Anthony O Omole, Hannah S Newton, Edward Cedrone, Kimia Nematpour, Shaojun Xie, Yongmei Zhao, Bao Tran, Marina A Dobrovolskaia, Nicole F Steinmetz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anthony O OmoleAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, San Diego, CA 92093, USA.
Hannah S NewtonNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
Edward CedroneNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
Kimia NematpourAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, San Diego, CA 92093, USA.
Shaojun XieSequencing Facility Bioinformatics Group, Biomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
Yongmei ZhaoSequencing Facility Bioinformatics Group, Biomedical Informatics and Data Science Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
Bao TranCCR Sequencing Facility, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
Marina A DobrovolskaiaNanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, USA.
Nicole F SteinmetzAiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, San Diego, CA 92093, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
Dual-pronged nano-drug delivery using plant virus-like particles.R01CA224605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Nicole Franziska Steinmetz · 2017 to 2026
$4.0M
Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian CancerR01CA253615 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, FIERING, STEVEN · 2020 to 2024
$3.1M
Toward translation of a plant virus-based in situ vaccination nanotechnologyR01CA274640 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIERING, STEVEN, RANJAN, ASHISH · 2022 to 2025
$2.5M
JEOL JEM-1400Plus Transmission Electron MicroscopeS10OD023527 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FARQUHAR, MARILYN GIST · 2017 to 2017
$579k
NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA224605NCI NIH HHS R01 CA253615NCI NIH HHS R01 CA274640NIGMS NIH HHS P41 GM103311NIH HHS 75N91019D00024NIH HHS S10 OD023527
6 · The paper itself

Abstract

Cowpea mosaic virus (CPMV) is a plant virus with potent anti-tumor efficacy. Intratumoral CPMV, but not cowpea chlorotic mottle virus (CCMV), reprograms the tumor microenvironment priming durable, systemic anti-tumor immunity. Here, we performed a side-by-side mechanism of action comparison between CPMV and CCMV. Through immune-multiplexing and trafficking studies we observed that CPMV and CCMV are taken up by innate immune cells at similar rates but are processed differently. While CCMV induces proinflammatory interleukins 22, 23, and 27, CPMV is a strong inducer of type I, II, and III interferons, which contribute to the activation and enhancement of immune cell function. We observed that CPMV RNAs activate Toll-like receptor (TLR) 7 upon delivery-and not CCMV RNAs; CPMV RNAs persist longer within cells compared with CCMV. Taken together, this work identifies determinants for CPMV's unique mechanism for intratumoral immunotherapy. It also broadens our understanding of the utility of plant viruses for biomedical applications.

Identifiers

PMID41737598
PMCPMC12927644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.